Rapid Antibody Testing for SARS-CoV-2 in Asymptomatic and Paucisymptomatic Healthcare Professionals in Hematology and Oncology Units Identifies Undiagnosed Infections

Paolo Corradini1,2, Giorgia Gobbi1, Filippo de Braud2,3, Jessica Rosa2, Chiara Rusconi1, Giovanni Apolone4, Cristiana Carniti1

Correspondence: Paolo Corradini (e-mail: paolo.corradini@unimi.it).

The emergence of coronavirus disease 2019 (COVID-19) represents a major threat for cancer patients and healthcare professionals. The huge numbers of infected patients globally and the continuous increase of newly diagnosed cases pose an unprecedented challenge to healthcare systems.1 The reasons for the widespread and rapid transmission of the infection are not completely certain and are provoking changes in public health recommendations as well as anxieties. Most patients in Hematology and Oncology (Hemat-Onc) units are immune-compromised because of cancer and cytotoxic treatments and are at high risk of developing life-threatening infections.2 In addition, an infected patient must delay treatment with potentially dangerous consequences.3

During the beginning of COVID-19 pandemic in Italy, the lack of meticulous contact tracing, the crowded emergency rooms, the shortage of personal protective equipments as well as the time required to set up hospital areas exclusively dedicated to COVID-19 patients, contributed to virus spreading. Within the hospitals, the Hemat-Onc units have been soon identified as COVID-free areas because of the patients’ frailty. The safety of patients and healthcare workers should have been a priority, but the dramatic emergency shifted all the efforts to critically ill patients more than to the other people represents a serious threat as a sizeable fraction of COVID-19 infections go undiagnosed.

Thus, considering that the large-scale use of nasopharyngeal swabs (NPS) is not realistic because of the limited testing capacities, the health authority discussion is now focused on the role of antibody testing to protect patients and workers to limit the risk of healthcare-associated infections. Under the hypothesis that serological testing for COVID-19 might be used to identify possible infected individuals, we conducted the first prospective study to evaluate the prevalence of seropositivity in asymptomatic or paucisymptomatic Hemat-Onc professionals.

At the Milano National Cancer Institute, Hemat-Onc doctors, nurses, paramedics and staff members were tested during the April 2020 pandemic peak. According to the presence of symptoms (rhinorrhea, pharyngitis, myalgia, fatigue, headache, anosmia, dysgeusia, nausea, diarrhea, cough, fever, dyspnea) in the previous 14 days, they were categorized as asymptomatic, symptomatic. Participants gave informed consent and the protocol was approved by Ethics Committee. We used a COVID-19 rapid immunochromatographic test for determination of antibodies in whole blood (PRIMA LAB SA, Switzerland) reported to have 98% specificity, 100% sensitivity, 98.6% accuracy for IgG and 96% specificity, 85% sensitivity, 92.9% accuracy for IgM. The presence of viral RNA was searched by reverse transcription polymerase chain reaction (RT-PCR) in NPS of seropositive cases only. Differences in the proportion of positive serological tests were assessed by Fisher exact test.

Twelve known symptomatic workers with a previously confirmed diagnosis of COVID-19 by RT-PCR of SARS-CoV-2 RNA in NPS, served as positive controls: 10 were IgG positive only (IgG+), 2 had IgG and IgM (IgM+/IgG). In this study, 234 asymptomatic or paucisymptomatic subjects were tested twice over a 2-week period of time as serology sensitivity is over 90% within 12 days after infection onset.4 Eleven of 194 (5.7%) asymptomatic workers were found to be positive: 7 were positive for IgG (IgG+) and 4 for IgM (IgM+). Among the seropositives, 4

1Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
2Dept. of Oncology and Hemato-oncology, University of Milano, Italy
3Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
4Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the copyright holder.
of the 7 IgG+ tested positive when the viral RNA was amplified in their NPS. In addition, 11 of 40 (27.5%) paucisymptomatic workers were found to be positive: 10 IgG+ (2 with a concomitant positive NPS) and 1 IgM+/IgG+ with a positive NPS (Table 1). Most frequent symptoms were anosmia (5), rhinorrhea (5), dysgeusia (4) and headache (4).

After 10 to 14 days, 204 subjects underwent a second round of testing and all results were confirmed, except for 2 IgM cases who were previously positive and now tested negative. In addition, 3 more asymptomatic workers became seropositive (2 IgG+ and 1 IgM+). These data indicate that the situation can change and that repeated testing can reveal false IgM positives, but also new occult infections.

Seropositivity rates were similar in all professional categories tested (doctors, nurses, paramedics or staff members). The percentage of seropositives was not higher in out-patient facilities (day-hospital and supportive care units) as compared to the in-patient wards. Total number of healthcare workers with documented diagnosis of COVID-19, since March 2020 in the Hemat-Onc units, was 12, although we are aware of possible underestimations as additional workers during this period, were left at home with influenza-like symptoms as a precautionary measure and underwent NPS only immediately before the readmission to work to certify their negativity. Thus collectively, considering a total of 246 Hemat-Onc workers, the estimate of documented diagnosis of COVID-19 by RT-PCR of SARS-CoV-2 RNA in NPS. These undocumented cases were likely to represent a real threat for patients, colleagues and also family contacts. Seropositivity was more frequent in the paucisymptomatic cohort (27.5% vs 5.7%, \( p < 0.002 \)). Our data indicate that even mild symptoms can herald a potentially infectious worker. Seropositive subjects should be strictly monitored, undergo NPS test and household quarantined when positive.

In conclusion, our study has several practical implications: (1) the prevalence of occult infections is not negligible in Hemat-Onc workers and it is similar to the general Italian population; (2) the screening with repeated serologic testing allows the identification of occult infected workers even when they are only IgG seropositive and limits the use of NPS; (3) both asymptomatic and paucisymptomatic workers can be potentially infectious and contribute to COVID-19 transmission.

**Acknowledgments**

We thank all the physicians, nurses, paramedics and staff members who participated in the study. Prof. Niccolò Bolli for critical reading of the manuscript. The study was supported in part by Associazione Italiana Leucemie Linfomi, Mielomi (AIL Milano).

**References**

1. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. *N Engl J Med*. 2020. In press.
2. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol*. 2020 March 26. [Epub ahead of print].

---

### Table 1

**Antibody Testing on Asymptomatic and Paucisymptomatic Healthcare Professionals.**

| Category                                      | Total positives | IgG positive | IgM positive | IgG and IgM positive | NPS positive/negative |
|-----------------------------------------------|-----------------|--------------|--------------|----------------------|-----------------------|
| Gender (male/female) NPS positive/negative    | 66/168          |              |              |                      |                       |
| Age, years (median)                           | 43              |              |              |                      |                       |
| Medical Doctors (N=101): 79 asymptomatic and 22 paucisymptomatic | 3 asymptomatic, 4 paucisymptomatic |              |              |                      |                       |
| Total positives: 7/101 (6.9%)                 |                 |              |              |                      |                       |
| IgG positive                                  | 7               |              |              |                      |                       |
| IgM positive                                  | 0               |              |              |                      |                       |
| IgG and IgM positive                          | 0               |              |              |                      |                       |
| NPS positive/negative                         | 3/4             |              |              |                      |                       |
| Nurses/Paramedics/staff members (N=133): 114 asymptomatic and 19 paucisymptomatic | 2 asymptomatic, 1 paucisymptomatic |              |              |                      |                       |
| Total positives: 15/133 (11.3%)               |                 |              |              |                      |                       |
| IgG positive                                  | 10              |              |              |                      |                       |
| IgM positive                                  | 4               |              |              |                      |                       |
| IgG and IgM positive                          | 1               |              |              |                      |                       |
| NPS positive/negative                         | 4/11            |              |              |                      |                       |
| NPS positive/negative                         |                 |              |              |                      |                       |

*Total positive 22 out of 234 (9.4%); NPS: nasopharyngeal swabs.*
3. van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020;26:665–671.
4. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 March 28. [Epub ahead of print].
5. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368:489–493.
6. Rosenbaum L. Facing Covid-19 in Italy - ethics, logistics, and therapeutics on the epidemic’s front line. N Engl J Med. 2020 March 18. [Epub ahead of print].
7. Mussetti A, Maluquer C, Albasanz-Puig A, et al. Handling the COVID-19 pandemic in the oncological setting. Lancet Haematol. 2020;7:e365.
8. Monica Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19. N Engl J Med. 2020 April 24. [Epub ahead of print].